A Phase 2 interventional study of Tonlamarsen and Placebo in Hypertension, Acute Severe Hypertension and Hypertensive Emergency, sponsored by Kardigan, Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Kardigan, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hypertensive Crisis with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Hypertensive Crisis · United States.
Among the 13 studies in Hypertensive Crisis with a site in United States, this one is the only one that started in 2026, is the only one in phase 2, and was the 13th registered.
31 studies on the registry are indexed under Hypertensive Crisis; 9 are open to participants now.
Browse Hypertensive Crisis studies →2 of the 13 studies in Hypertensive Crisis with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Hypertensive Crisis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 140 is close to the median of 140 across 19 interventional studies indexed under Hypertensive Crisis.
Median enrollment 160 across the 9 interventional studies, 186 across the 4 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 5 most frequent:
Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Kardigan, Inc. has 1 study filed under Hypertensive Crisis — fewer than ten, so there is no comparison to draw.
1 of the studies in Hypertensive Crisis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07511361Kardigan, Inc.Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Hypertensive Crisis with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the blood pressure-lowering effect of tonlamarsen in adult participants who were recently hospitalized and concurrently experienced an episode of acute severe hypertension.
The Sponsor is studying an investigational medication called tonlamarsen to determine if it can help people recently treated for acute severe hypertension (hypertensive emergency and urgency).
The purpose of this study is to evaluate how well tonlamarsen works compared to a placebo and to see how safe it is for people following a recent episode of acute severe hypertension. Tonlamarsen is designed to block the body's liver from making a protein called angiotensinogen (AGT), which plays a key role in controlling blood pressure.
The main goals of the study are:
Participants will:
31 studies on the registry are indexed under Hypertensive Crisis; 9 are open to participants now.
This study's planned enrollment of 140 is close to the median of 140 across 19 interventional studies indexed under Hypertensive Crisis.
Browse Hypertensive Crisis studies →Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Compared within Hypertensive Crisis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)
Drug: Tonlamarsen
3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks)
Drug: Placebo
Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study
Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study
Part A: To assess variability in clinical and biomarker measures to inform Part B sample-size estimation and study-design assumptions
* Change from baseline in plasma angiotensinogen (AGT) levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure
Time frame: Baseline through Week 12
Part B: To assess the pharmacodynamic (PD) effect of tonlamarsen on plasma AGT levels
Percent change in plasma AGT levels from Baseline to Week 4
Time frame: Week 4
Part A: To assess the safety and tolerability of tonlamarsen compared with placebo
* Incidence and severity of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) * Incidence of clinically significant abnormalities in laboratory assessments, physical examinations, 12-lead electrocardiograms, and vital signs
Time frame: Week 36
Part A: To assess the feasibility of using AGT levels and systolic blood pressure as efficacy endpoints
* Change from baseline in plasma AGT levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure
Time frame: Baseline through Week 12
Part B: To assess the safety and tolerability of tonlamarsen compared with placebo
* Incidence and severity of treatment emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) * Incidence of clinically significant abnormalities in laboratory assessments, physical examinations, 12-lead electrocardiograms, and vital signs
Time frame: Week 36
Part B: To evaluate the effect of tonlamarsen on systolic blood pressure measured via daily home blood pressure monitoring
Change in time-averaged systolic blood pressure measured via daily home blood pressure monitoring from Baseline during Week 4
Time frame: Week 4
Part B: To evaluate the effect of tonlamarsen on office systolic blood pressure
Change in office systolic blood pressure from Baseline to Week 4
Time frame: Week 4
Part B: To assess the PD effect of tonlamarsen on plasma AGT levels
Percent change in plasma AGT levels from Baseline to Week 12
Time frame: Week 12
Part B: To evaluate the effect of tonlamarsen on systolic blood pressure measured via daily home blood pressure monitoring
Change in time-averaged systolic blood pressure measured daily via home blood pressure monitoring from Baseline during Week 12
Time frame: Week 12
Part B: To evaluate the effect of tonlamarsen on office systolic blood pressure
Change in office systolic blood pressure from Baseline to Week 12
Time frame: Week 12
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2026, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tonlamarsen
Kardigan, Inc.